Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

Yingjie Bian, Zheng Zhang, Zhichen Sun, Juanjuan Zhao, Danming Zhu, Yang Wang, Sherry Fu, Jingya Guo, Longchao Liu, Lishan Su, Fu Sheng Wang, Yang Xin Fu, Hua Peng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1 rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infection in carrier mice. Conclusion: These results suggest that preS1 can function as a therapeutic vaccine for the control of CHB. (Hepatology 2017;66:1067-1082).

Original languageEnglish (US)
Pages (from-to)1067-1082
Number of pages16
JournalHepatology
Volume66
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Immune Tolerance
Hepatitis B virus
Hepatitis B Surface Antigens
Vaccines
Chronic Hepatitis B
Vaccination
Virus Diseases
Virion
Peptides
Hepatitis B Antibodies
Therapeutic Uses
Gastroenterology
Surface Antigens
Hepatocytes
Therapeutics
Animal Models
Infection

ASJC Scopus subject areas

  • Hepatology

Cite this

Bian, Y., Zhang, Z., Sun, Z., Zhao, J., Zhu, D., Wang, Y., ... Peng, H. (2017). Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology, 66(4), 1067-1082. https://doi.org/10.1002/hep.29239

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. / Bian, Yingjie; Zhang, Zheng; Sun, Zhichen; Zhao, Juanjuan; Zhu, Danming; Wang, Yang; Fu, Sherry; Guo, Jingya; Liu, Longchao; Su, Lishan; Wang, Fu Sheng; Fu, Yang Xin; Peng, Hua.

In: Hepatology, Vol. 66, No. 4, 01.10.2017, p. 1067-1082.

Research output: Contribution to journalArticle

Bian, Y, Zhang, Z, Sun, Z, Zhao, J, Zhu, D, Wang, Y, Fu, S, Guo, J, Liu, L, Su, L, Wang, FS, Fu, YX & Peng, H 2017, 'Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice', Hepatology, vol. 66, no. 4, pp. 1067-1082. https://doi.org/10.1002/hep.29239
Bian, Yingjie ; Zhang, Zheng ; Sun, Zhichen ; Zhao, Juanjuan ; Zhu, Danming ; Wang, Yang ; Fu, Sherry ; Guo, Jingya ; Liu, Longchao ; Su, Lishan ; Wang, Fu Sheng ; Fu, Yang Xin ; Peng, Hua. / Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. In: Hepatology. 2017 ; Vol. 66, No. 4. pp. 1067-1082.
@article{6e52539867f8486e80061ce2a2298ec1,
title = "Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice",
abstract = "Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1 rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infection in carrier mice. Conclusion: These results suggest that preS1 can function as a therapeutic vaccine for the control of CHB. (Hepatology 2017;66:1067-1082).",
author = "Yingjie Bian and Zheng Zhang and Zhichen Sun and Juanjuan Zhao and Danming Zhu and Yang Wang and Sherry Fu and Jingya Guo and Longchao Liu and Lishan Su and Wang, {Fu Sheng} and Fu, {Yang Xin} and Hua Peng",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/hep.29239",
language = "English (US)",
volume = "66",
pages = "1067--1082",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

AU - Bian, Yingjie

AU - Zhang, Zheng

AU - Sun, Zhichen

AU - Zhao, Juanjuan

AU - Zhu, Danming

AU - Wang, Yang

AU - Fu, Sherry

AU - Guo, Jingya

AU - Liu, Longchao

AU - Su, Lishan

AU - Wang, Fu Sheng

AU - Fu, Yang Xin

AU - Peng, Hua

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1 rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infection in carrier mice. Conclusion: These results suggest that preS1 can function as a therapeutic vaccine for the control of CHB. (Hepatology 2017;66:1067-1082).

AB - Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance. Our study showed that this preS1-polypeptide rather than HBsAg vaccination induced robust immune responses in HBV carrier mice. The anti-preS1 rapidly cleared HBV virions in vivo and blocked HBV infection to hepatocytes in vitro. Intriguingly, vaccination of preS1-polypeptide even reduced the tolerized status of HBsAg, opening a therapeutic window for the host to respond to the HBsAg vaccine. A sequential administration of antigenically distinct preS1-polypeptide and HBsAg vaccines in HBV carrier mice could finally induce HBsAg/hepatitis B surface antibody serological conversion and clear chronic HBV infection in carrier mice. Conclusion: These results suggest that preS1 can function as a therapeutic vaccine for the control of CHB. (Hepatology 2017;66:1067-1082).

UR - http://www.scopus.com/inward/record.url?scp=85024111410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024111410&partnerID=8YFLogxK

U2 - 10.1002/hep.29239

DO - 10.1002/hep.29239

M3 - Article

C2 - 28445927

AN - SCOPUS:85024111410

VL - 66

SP - 1067

EP - 1082

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -